Genmab A/S

42.86-0.9500-2.17%Vol 445.22K1Y Perf 15.92%
Sep 15th, 2021 16:00 DELAYED
BID42.83 ASK42.87
Open43.27 Previous Close43.81
Pre-Market- After-Market-
 - -%  - -
Target Price
44.30 
Analyst Rating
Strong Buy 1.21
Potential %
3.36 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     56.96
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★★     76.02
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
67.26 
Earnings Rating
Market Cap28.15B 
Earnings Date
3rd Nov 2021
Alpha0.01 Standard Deviation0.09
Beta0.57 

Today's Price Range

42.7943.28

52W Range

30.1049.07

5 Year PE Ratio Range

31.80106.20

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Sell
Performance
1 Week
-4.44%
1 Month
-7.51%
3 Months
-3.84%
6 Months
27.41%
1 Year
15.92%
3 Years
151.97%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
GMAB42.86-0.9500-2.17
AAPL149.030.91000.61
GOOG2 904.1236.00001.26
MSFT304.825.03001.68
XOM56.421.84003.37
WFC46.640.59001.28
JNJ165.420.62000.38
FB373.92-2.6100-0.69
GE102.161.78001.77
JPM158.161.09000.69
Earnings HistoryEstimateReportedSurprise %
Q02 20210.080.080.00
Q01 20210.040.27575.00
Q04 20200.120.1416.67
Q03 20200.080.1362.50
Q02 20200.880.76-13.64
Q01 20200.020.06200.00
Q04 20190.360.34-5.56
Q03 20190.081.261.48K
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date3rd Nov 2021
Estimated EPS Next Report0.11
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume445.22K
Shares Outstanding656.81M
Shares Float653.82M
Trades Count5.97K
Dollar Volume40.78M
Avg. Volume521.68K
Avg. Weekly Volume457.04K
Avg. Monthly Volume383.50K
Avg. Quarterly Volume483.88K

Genmab A/S (NASDAQ: GMAB) stock closed at 42.86 per share at the end of the most recent trading day (a -2.17% change compared to the prior day closing price) with a volume of 445.54K shares and market capitalization of 28.15B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 781 people. Genmab A/S CEO is Jan G. J. van de Winkel.

The one-year performance of Genmab A/S stock is 15.92%, while year-to-date (YTD) performance is 5.41%. GMAB stock has a five-year performance of %. Its 52-week range is between 30.1 and 49.07, which gives GMAB stock a 52-week price range ratio of 67.26%

Genmab A/S currently has a PE ratio of 69.20, a price-to-book (PB) ratio of 9.09, a price-to-sale (PS) ratio of 24.87, a price to cashflow ratio of 32.00, a PEG ratio of 2.32, a ROA of 11.66%, a ROC of 12.00% and a ROE of 13.20%. The company’s profit margin is 34.33%, its EBITDA margin is 42.10%, and its revenue ttm is $1.16 Billion , which makes it $1.77 revenue per share.

Of the last four earnings reports from Genmab A/S, there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.11 for the next earnings report. Genmab A/S’s next earnings report date is 03rd Nov 2021.

The consensus rating of Wall Street analysts for Genmab A/S is Strong Buy (1.21), with a target price of $44.3, which is +3.36% compared to the current price. The earnings rating for Genmab A/S stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Genmab A/S has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Genmab A/S has a Sell technical analysis rating based on Technical Indicators (ADX : 23.16, ATR14 : 0.99, CCI20 : -178.18, Chaikin Money Flow : -0.31, MACD : -0.48, Money Flow Index : 33.05, ROC : -8.98, RSI : 31.71, STOCH (14,3) : 1.11, STOCH RSI : 0.00, UO : 20.87, Williams %R : -98.89), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Genmab A/S in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (71.43 %)
5 (71.43 %)
5 (71.43 %)
Moderate Buy
2 (28.57 %)
2 (28.57 %)
2 (28.57 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.21
Strong Buy
1.21
Strong Buy
1.21

Genmab A/S

Genmab is a Copenhagen-based cancer drug developer best known for its antibody technology platforms, DuoBody and HexaBody, and multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company is the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis) and has several pipeline candidates targeting other oncologic indications and autoimmune diseases.

CEO: Jan G. J. van de Winkel

Telephone: +45 70202728

Address: Kalvebod Brygge 43, Copenhagen V 1560, , DK

Number of employees: 781

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

58%42%

TipRanks News for GMAB

News

Stocktwits